End-to-End Gap Analysis of the Raw Data, Compilation and Submission to the USFDA

A U.S. based client who is into generic pharmaceutical manufacturing was facing challenges in reviewing of the raw data, impact analysis of the changes, compilation of the affected sections including administrative documents and submission to the USFDA. Freyr supported the client by performing a detailed Gap Analysis and suggested solutions within the timeline.

Read the case to know Freyr’s expertise in submissions to the USFDA.

Fill the form below to download the Case Study